ResMed (RMD)
(Delayed Data from NYSE)
$189.35 USD
+2.41 (1.29%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $189.26 -0.09 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RMD 189.35 +2.41(1.29%)
Will RMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RMD
4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
Other News for RMD
10 Health Care Stocks Whale Activity In Today's Session
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
Disney, MicroStrategy initiated: Wall Street's top analyst calls
Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Oppenheimer downgrades ResMed on sleep apnea GLP-1 risk